Introduction
Plant-derived cannabinoids such as delta-9-tetrahydrocannabinol (THC) have been used for medicinal purposes for thousands of years (9) . Two G-protein coupled receptors termed CB1 and CB2 were identified in the early 1990s as receptors for cannabinoids (16, 17) . Shortly after the cloning of these receptors, mediators were discovered that serve as endogenous ligands for these receptors and termed endocannabinoids (9) .
Endocannabinoids are arachidonic acid-derived lipid mediators with various selectivity for endocannabinoid receptors as well as other targets. Arachidonoyl ethanolamine (Anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) are the best characterized endocannabinoids. Endocannabinoids, their receptors and molecules that are responsible for endocannabinoid biosynthesis, uptake and degradation collectively form the endocannabinoid system. The endocannabinoid system is involved in the regulation of a variety of physiological processes including nociception, food intake, intestinal motility, lipogenesis and inflammation (for review see (9) ). Although CB1 and CB2 receptors display the highest expression in the brain and the immune system, respectively, they are also present in many other tissues including the liver, and have been implicated in the pathophysiology of inflammatory and metabolic diseases such as artherosclerosis, inflammatory bowel disease and fatty liver. The important role of endocannabinoids in disease processes of peripheral tissues and the finding that components of the endocannabinoid system are expressed in the injured liver has led to detailed studies on the role of the endocannabinoid system in hepatic injury and wound-healing responses.
Pathophysiology of hepatic fibrogenesis
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Liver fibrosis is the common wound-healing response to chronic hepatic damage of various etiologies including alcohol abuse, viral and parasitic infection, nonalcoholic steatohepatitis, drugs, iron and copper overload, and autoimmune diseases (2) . Acute liver injury leads to a limited wound-healing response and a temporary increase in a collagen-rich extracellular matrix (ECM), which provides a scaffold for the restoration of liver architecture and function. In contrast, chronic liver injury is associated with a chronic and exaggerated deposition of ECM that undergoes additional changes that render it more resistant to degradation. In advanced stages of injury, hepatocytes are replaced by abundant ECM leading to decreased liver function as well as increased vascular resistance and portal hypertension. Hepatic stellate cells (HSCs, also known as Ito cells, fat storing cells or hepatic lipocytes) have been shown to be a predominant source of ECM in the fibrotic liver (2) . In the normal liver, HSCs produce only negligible amounts of ECM and their main function is the storage of large amounts vitamin A.
Following liver injury, HSCs activate and transdifferentiate into myofibroblast-like cells that express large amounts of ECM proteins, acquire contractile properties and secrete pro-inflammatory mediators (2) . In recent years, it has been suggested that ECMproducing myofibroblasts can also derive from other sources, including portal fibroblasts and bone marrow. Moreover, it has been proposed that hepatocytes undergo epithelialmesenchymal transition and contribute to the pool of myofibroblasts in the injured liver.
While it is currently accepted that HSCs are not the only source of ECM in the fibrotic liver, the contribution of portal fibroblasts, bone marrow and hepatocytes to ECM synthesis needs to be further characterized in different types of liver injury.
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Removal of the causative agent is the most effective therapy for treating hepatic fibrosis (2) . Following eradication of hepatitis C virus infection, cessation of alcohol abuse, treatment of hemochromatosis or resolution of biliary obstruction, liver fibrosis can significantly reverse and sometimes even result in a completely normal hepatic architecture (2) . Fibrosis resolution is preceded by the disappearance of activated HSCs, suggesting that endogenous mediators in the liver either reverse HSC activation or induce cell death in HSCs. There is a growing body of evidence that HSCs undergo apoptosis during the resolution of hepatic fibrosis, and that the selective induction of HSC cell death may be a tool to reduce fibrogenesis under circumstances in which the underlying disease cannot be cured (12) . Endocannabinoids are among the most potent endogenous inducers of HSC death in vitro suggesting that they may be involved in limiting hepatic fibrogenesis in vivo. Currently, there is no effective treatment for hepatic fibrosis except treating the underlying disease. New concepts for the treatment of hepatic fibrosis focus on pathways that mediate HSC activation and proliferation as well as mediators that induce cell death of HSCs. Therefore, endocannabinoids have received much attention as potential anti-fibrogenic mediators.
Endocannabinoids and endocannabinoid-degrading enzymes in the normal and fibrotic liver
The normal liver contains only low levels of the endocannabinoids AEA and 2-AG (13, 18, 21, 23, 25) . This is, at least in part, the result of high hepatocellular expression of fatty acid amide hydrolase (FAAH), the most important enzyme for AEA degradation (6) .
Activation of the hepatic endocannabinoid system can be detected already in early stages of liver disease. Hepatic and serum levels of AEA increase within days of liver disease such as fatty liver and acute hepatitis (5, 18) . In fatty liver, elevation was not caused by an upregulation of the synthesis pathway of AEA, but by a decrease in AEA degradation by FAAH (see article by Kunos et al in this Themes series.). In the early stages of cholestatic liver disease, FAAH mRNA and FAAH activity are also decreased (23) supporting the hypothesis that changes in endocannabinoid degradation are an important mechanism to control endocannabinoid levels in the liver. The levels of 2-AG are also significantly upregulated in acute liver injury induced by bile ligation or injection of a single dose of CCl 4 (22) . However, it remains to be investigated whether a decline in the expression of MGL, the primary enzyme for 2-AG degradation (10) , contributes to the increase of 2-AG levels in the acutely injured liver. In the later stages of liver fibrosis, hepatic or serum levels of endocannabinoids remain significantly increased. While data on endocannabinoid levels in early liver injury are limited to rodents, it has been shown that endocannabinoids are elevated in patients with advanced liver disease. Patients with liver cirrhosis display high serum levels of AEA (5) as well as increased levels of AEA in circulating monocytes (3, 19) . Lipopolysaccharide (LPS) induces AEA levels in macrophages and this process is, at least in part, dependent on NF-B (14) . The LPSinduced increase in AEA levels in macrophages is mediated by de novo synthesis and not by reduced degradation, since LPS fails to decrease FAAH expression and activity (14) .
The synthesis of 2-AG in macrophages can also be triggered by LPS, but to a much lesser extent. The well-documented elevations of LPS in hepatic fibrosis (20) suggest that LPS is a key trigger of endocannabinoid synthesis in the fibrotic liver. A role of other mediators and pathways in hepatic endocannabinoid synthesis is likely, but has not yet Page 6 of 24 been determined. Moreover, there is no data on the contribution of other cell types, such as hepatocytes or HSCs, to endocannabinoid synthesis in early and late stages of liver disease. However, it is well known that hepatocytes express high levels of FAAH (23) . In mice, hepatic FAAH expression and activity are the highest in the body and even exceed those of the brain. This implies a crucial role for hepatocytes in limiting hepatic endocannabinoid levels. Additionally, high levels of FAAH render hepatocytes resistant to endocannabinoid-induced signals (23) . In contrast to hepatocytes, HSCs do not express significant amounts of FAAH and are therefore more sensitive to AEA. There are no significant differences in MGL expression between hepatocytes and HSCs (22) .
Endocannabinoid receptors in the normal and fibrotic liver
The expression of endocannabinoid receptors is nearly undetectable in the normal liver providing further evidence to the notion that the endocannabinoid system is in a low activation state in the normal liver (13, 18, 25) . Both CB1 and CB2 receptors are upregulated in the early stages of liver injury. Expression levels remains elevated in the late stages of liver injury, but strong upregulation of CB1 occurs only in some types of liver injury whereas CB2 is strongly upregulated in all types of liver injury (4, 13, 18, 21, 25) . CB1 receptors are significantly upregulated in the vascular endothelium as well as in myofibroblasts located in fibrotic bands of cirrhotic livers in humans and rodents (25). 
Role of the endocannabinoid system in hepatic fibrogenesis
The crucial role of the endocannabinoid system in hepatic fibrosis has been highlighted by recent studies in which CB1 and CB2 receptors were blocked using both genetic and pharmacologic approaches. Interestingly, CB1 and CB2 exert opposing effects on fibrogenesis, suggesting that the endocannabinoid system regulates both pro-and antifibrogenic responses in the liver (see Fig. 1 ). CB1-deficient mice show a strong decrease in fibrogenesis induced by CCL 4 , thioacetamide or bile duct ligation (25), whereas CB2-deficient mice display an increase in fibrogenesis following CCL 4 treatment (13). The pro-fibrogenic function of the CB1 receptor in the liver is further emphasized by the ability of the CB1 inhibitor rimonabant to reduce profibrogenic markers such as TGF-1 and -SMA as well as histological fibrosis after bile duct Page 8 of 24 ligation or treatment with thioacetamide or CCl 4 (25). It was suggested that an increase in cell death and a reduced proliferation of myofibroblasts are responsible for the observed decrease in fibrosis after CB1 antagonism. The effects of CB2 antagonism appear to be exactly opposite of CB1 antagonism, namely decreased myofibroblast cell death and enhanced proliferation (13) . Interestingly, patients with chronic hepatitis C and daily marijuana consumption displayed more severe fibrosis progression than non-consumers, suggesting that profibrogenic CB1 signals dominate over antifibrogenic CB2 signals (11).
However, one has to keep in mind that CB2 is predominantly expressed in monocytic cell types and that it exerts immunosuppressive effects which may have confounding effects in patients with chronic hepatitis C as these patients require an intact immune response to keep the hepatitis C virus in check. It is conceivable that chronic marijuana consumption promotes fibrogenesis in chronic hepatitis C via CB2-mediated suppression of anti-viral immunity (21) (see Fig. 1 ).
A main weakness of current study designs is their inability to pinpoint cellular targets of endocannabinoids in vivo. While the above described studies postulate that the pro-and antifibrogenic effects of CB1 and CB2 receptors are predominantly mediated through hepatic myofibroblasts, it is possible that other cell types make major contributions, as it has been shown that CB1 and CB2 are highly expressed in other hepatic cell types. In the injured liver, CB1 is expressed on the vascular endothelium and in hepatocytes and may thus alter the response to injury in these cell types. As CB2 is predominantly expressed in monocytic cell types and exerts strong anti-inflammatory effects, CB2 may mediate its anti-fibrotic actions through anti-inflammatory signals in patients with non-viral causes of hepatic fibrosis. Thus, investigations in isolated hepatic cell populations as well as in mouse models with cell-specific CB1 and CB2 deletions are required to further understand the targets of endocannabinoids and to determine how CB1 and CB2-mediated signals modulate fibrogenesis. Also, the liver is innervated with axonal processes of autonomic nerve fibers being in close contact with HSCs, raising the possibility that cannabinoid receptors could influence this interaction, and thereby HSC activation and fibrogenesis. Currently, it is believed the regulation of cell death and proliferation in fibrogenic cell types are the two main mechanisms by which endocannabinoids influence hepatic fibrogenesis (see Fig.1 ). The modulation of immune responses comprises a third potential mechanism by which endocannabinoids modify wound-healing responses in the liver.
Effects of endocannabinoids on hepatic cell populations
Endocannabinoid-induced cell death
There is a growing body of evidence that endocannabinoids control cell death and survival both in vitro and in vivo (15) . In many cell types, endocannabinoids induce apoptotic cell death at supraphysiological concentrations in the micromolar range.
Endocannabinoids mediate apoptosis not only through CB1 and CB2, but also through TRPV1, which also acts as receptor for anandamide, and in a receptor-independent manner.
The role of AEA in cell death regulation is well studied whereas there is little data on cell death induction by other endocannabinoids. Several mechanisms of AEA-induced cell activation in a CB receptor-independent manner (13, 22) . It should be emphasized that in vivo concentrations of 2-AG are about 100-fold higher than those of AEA and that 2-AG is thus more likely to reach the threshold for cell death induction in vivo. In some cell types including neuronal cells, CB1 or CB2 receptors prevent apoptosis by activating cytoprotective pathways such as phosphatidylinositol 3-kinase through CB1. This is of interest as HSCs share many features and molecular markers with neuronal cells.
Hepatic stellate cells are highly sensitive to cell death induction by exo-and endocannabinoids (13, 22, 24) . Cell death induction by endocannabinoids such as AEA and 2-AG requires the presence of membrane cholesterol, but not CB1, CB2 or TRPV1 (13, 22, 24) , whereas cell death induced by exocannabinoids requires CB2 (13).
Endocannabinoids induce a rapid increase of mitochondrial ROS production which is responsible for the induction of cell death as shown by the ability of various antioxidants to block 2-AG-and AEA-mediated cell death in HSCs (see Fig. 2 
Endocannabinoids and myofibroblast proliferation
Proliferation of HSCs and myofibroblasts is a crucial feature of hepatic fibrogenesis and increases the pool of activated myofibroblasts in the liver. Endocannabinoids including 2-AG and AEA exert antiproliferative actions in a wide spectrum of cell lines as well as primary cells. Several pathways are believed to contribute to endocannabinoid-induced growth arrest such as (i) Inhibition of p21ras, and the ras cascade-dependent proliferation in tumors, and (ii) prolonged activation of ERK, which does not induce, but instead inhibits proliferation; and (iii) inhibition of growth factor signaling. However, in some cell types such as lymphocytes and neuronal cells, AEA as well as 2-AG can also induce proliferation in certain stages of cell development by a CB receptor-mediated mechanism which is preceded by ERK activation.
We and others have shown that non-toxic concentrations of AEA or 2-AG significantly reduce HSC proliferation in the presence of PDGF (13, 24) . Endocannabinoids reduce myofibroblast proliferation in a receptor-independent manner, whereas exocannabinoids such as THC decrease myofibroblast proliferation in a CB2-dependent manner (13, 24) .
Similar to neuronal cells, myofibroblasts appear to proliferate in response to CB1 activation. Although a direct pro-proliferative effect of endocannabinoids has not been demonstrated in hepatic myofibroblasts, CB1-deficient myofibroblasts displayed a strong decrease in spontaneous proliferation in the absence of endocannabinoids which was postulated to be mediated by the same ligand-independent CB1 signals that mediate antiapopototic signals in myofibroblasts (25). CB1-deficient myofibroblasts displayed a decrease in ERK and Akt phosphorylation, two kinases that are crucial for proliferation in hepatic myofibroblasts and HSCs (25). One should keep in mind that in vivo concentrations of endocannabinoids are lower than the concentrations that were associated with anti-proliferative effects in vitro. Thus, it is possible that ligand-independent CB1-mediated pro-proliferative effects dominate over CB2-dependent and CB receptor-independent anti-proliferative effects during fibrogenesis. 
Anti-inflammatory effects of endocannabinoids
Conclusions and future directions
There is overwhelming evidence that the endocannabinoid system plays a major role in the pathophysiology of chronic liver injury and wound healing responses, and that modulation of the endocannabinoid system may be exploited for the treatment of liver fibrosis. Among all candidates, CB1 represents the most promising target for antifibrotic therapies. In addition to the antifibrogenic effects of CB1 blockade, one can expect positive effects on other complications such as portal hypertension, ascites formation, hepatic encephalopathy and cardiomyopathy. Moreover, CB1 antagonism appears to have beneficial effects on hepatic steatosis, a common feature in many subsets of patients with liver fibrosis, and on the hormone levels of the fibrosis-modulating hormones leptin and adiponectin (8, 18) . Other strategies to target the endocannabinoid system in hepatic fibrosis, e.g. activating CB2 by specific agonists or modulating the levels of endocannabinoids by targeting endocannabinoid degrading enzymes deserve further evaluation. It is possible that CB1 antagonism not only inhibits CB1-mediated profibrogenic signals, but also enhances CB2-dependent and CB receptor-independent anti-fibrogenic effects by making more ligand available to these pathways. Despite mounting evidence for role of the endocannabinoid system in fibrogenesis, there is still a considerable lack of knowledge about the cellular targets of endocannabinoids and the molecular mechanisms that mediate the effects of endocannabinoids. One important question that needs to be answered is whether a yet-unidentified endocannabinoid mediates CB1-dependent profibrogenic effects or whether CB1 receptors generate profibrogenic signals in a ligand-independent manner. Moreover, further studies are needed to investigate the potential role of CB2-dependent anti-inflammatory effects in fibrogenesis and the ability and relevance of endocannabinoid-mediated cell death of fibrogenic cells in vivo. The generation of mice with cell-specific deletion of components of the endocannabinoid system will answer some of these questions in the future. Most importantly, it needs to be determined whether CB1 antagonism is a feasible strategy in patients with fibrosis as the concentrations of the CB1 antagonist rimonabant that were required to block fibrogenesis in mice were 20-fold higher than those used in overweight patients. Thus, chances of side effects of CB1 antagonists such as depression may be even higher, and results of current investigations on the safety of CB1 antagonists should be awaited before their use in patients with fibrosis should be considered.
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